Selective Androgen Receptor Modulators (SARMs) Effects on Physical Performance: A Systematic Review of Randomized Control Trials

IF 3 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Clinical Endocrinology Pub Date : 2024-09-16 DOI:10.1111/cen.15135

Jimmy Wen, Burhaan Syed, Jared Leapart, Mouhamad Shehabat, Ubaid Ansari, Muzammil Akhtar, Daniel Razick, David Pai

{"title":"Selective Androgen Receptor Modulators (SARMs) Effects on Physical Performance: A Systematic Review of Randomized Control Trials","authors":"Jimmy Wen, Burhaan Syed, Jared Leapart, Mouhamad Shehabat, Ubaid Ansari, Muzammil Akhtar, Daniel Razick, David Pai","doi":"10.1111/cen.15135","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>Selective androgen receptor modulators (SARMs) are potential treatments for ameliorating age-related physical dysfunctions caused by sarcopenia, cachexia and chronic illnesses such as cancer. The purpose of this systematic review is to analyse the effect of SARMs on physical performance and body and evaluate their safety profile.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A systematic review search criteria following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines was performed in three databases for studies reporting physical parameter outcomes after SARM intervention. Study variables included title, author, publication date, study year, number of patients, dosage, mean age, mean follow-up time, pre and post-intervention outcomes and rates of complications.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Nine studies, including 970 patients with a mean age of 57.1 years (35.3−75.9) and a mean follow-up of 80 days (14−180), were included. Six SARMs were analysed: LGD-4033, PF-06260414, GSK2881078, GTx-024, MK-0773 and OPK-88004. Mean pre-intervention stair climbing power (five studies), one repetition maximum leg press (four studies) and short physical performance battery (SPPB) score (two studies), lean body mass (seven studies) and fat mass (five studies) were 352.24 W (69.79−678.7), 1822.77 N (1176.8−2407.3), 9.15 (7.95−9.9), 49.46 kg (30.94−63.9) and 21.99 kg (13.3−33), respectively. Mean post-intervention values were 315.16 W (89.46−525.73 W), 2191.27 N (1375.87−2462.9 N), 9.79 (8.88−10.4), 50.86 kg (31.02−67.29) and 21.85 kg (12.54−32.16), respectively.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>SARMs have a positive effect on physical performance and body composition and are associated with moderate rates of mild to moderate adverse effects (AEs) and a low rate of severe AEs.</p>\n </section>\n </div>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":"102 1","pages":"3-27"},"PeriodicalIF":3.0000,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cen.15135","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cen.15135","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

Selective androgen receptor modulators (SARMs) are potential treatments for ameliorating age-related physical dysfunctions caused by sarcopenia, cachexia and chronic illnesses such as cancer. The purpose of this systematic review is to analyse the effect of SARMs on physical performance and body and evaluate their safety profile.

Methods

A systematic review search criteria following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines was performed in three databases for studies reporting physical parameter outcomes after SARM intervention. Study variables included title, author, publication date, study year, number of patients, dosage, mean age, mean follow-up time, pre and post-intervention outcomes and rates of complications.

Results

Nine studies, including 970 patients with a mean age of 57.1 years (35.3−75.9) and a mean follow-up of 80 days (14−180), were included. Six SARMs were analysed: LGD-4033, PF-06260414, GSK2881078, GTx-024, MK-0773 and OPK-88004. Mean pre-intervention stair climbing power (five studies), one repetition maximum leg press (four studies) and short physical performance battery (SPPB) score (two studies), lean body mass (seven studies) and fat mass (five studies) were 352.24 W (69.79−678.7), 1822.77 N (1176.8−2407.3), 9.15 (7.95−9.9), 49.46 kg (30.94−63.9) and 21.99 kg (13.3−33), respectively. Mean post-intervention values were 315.16 W (89.46−525.73 W), 2191.27 N (1375.87−2462.9 N), 9.79 (8.88−10.4), 50.86 kg (31.02−67.29) and 21.85 kg (12.54−32.16), respectively.

Conclusion

SARMs have a positive effect on physical performance and body composition and are associated with moderate rates of mild to moderate adverse effects (AEs) and a low rate of severe AEs.

Abstract Image

查看原文本刊更多论文

选择性雄激素受体调节剂 (SARMs) 对运动表现的影响：随机对照试验的系统回顾

目的选择性雄激素受体调节剂（SARMs）是一种潜在的治疗方法，可改善因肌肉疏松症、恶病质和癌症等慢性疾病引起的与年龄相关的身体机能障碍。本系统性综述的目的是分析 SARM 对身体表现和身体的影响，并评估其安全性。方法按照系统性综述和荟萃分析首选报告项目（PRISMA）指南的系统性综述检索标准，在三个数据库中检索报告 SARM 干预后身体参数结果的研究。研究变量包括标题、作者、发表日期、研究年份、患者人数、剂量、平均年龄、平均随访时间、干预前后的结果以及并发症发生率。分析了六种 SARM：LGD-4033、PF-06260414、GSK2881078、GTx-024、MK-0773 和 OPK-88004。干预前的平均爬楼梯力量（5 项研究）、单次最大压腿力量（4 项研究）和短期体能测试（SPPB）得分（2 项研究）、瘦体重（7 项研究）和脂肪量（5 项研究）分别为 352.24 W（69.79-678.7）、1822.77 N（1176.8-2407.3）、9.15（7.95-9.9）、49.46 kg（30.94-63.9）和 21.99 kg（13.3-33）。干预后的平均值分别为 315.16 W（89.46-525.73 W）、2191.27 N（1375.87-2462.9 N）、9.79（8.88-10.4）、50.86 kg（31.02-67.29）和 21.85 kg（12.54-32.16）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Endocrinology 医学-内分泌学与代谢

CiteScore

6.40

自引率

3.10%

发文量

192

审稿时长

1 months

期刊介绍： Clinical Endocrinology publishes papers and reviews which focus on the clinical aspects of endocrinology, including the clinical application of molecular endocrinology. It does not publish papers relating directly to diabetes care and clinical management. It features reviews, original papers, commentaries, correspondence and Clinical Questions. Clinical Endocrinology is essential reading not only for those engaged in endocrinological research but also for those involved primarily in clinical practice.